Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year. New, potentially ...

AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate (ADC) Enhertu has chalked up another win in an early breast cancer setting, this time besting Roche’s Kadcyla in a phase 3 study. Enhertu ...

Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), ...

Please provide your email address to receive an email when new articles are posted on . A novel assay may help direct antibody-drug conjugate therapy through measurements of HER2 and TROP2. Most ...

Simtra BioPharma Solutions, a CDMO, formed a five-year strategic alliance with the life science business of Germany-based Merck KGaA, which operates as MilliporeSigma in the U.S. and Canada. The ...

Researchers have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results, the approach combined the benefits of ...

ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put billions ...

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...

CBX-12 targets tumor cells with exatecan, offering potential for patients ineligible for antigen-targeted therapies. Phase 2 trial evaluates CBX-12's safety, tolerability, and efficacy in ...